Investors·2025-11-10 14:52Core Viewpoint - Pfizer is set to acquire Metsera for up to $10 billion, following a competitive bidding process with Novo Nordisk, which has raised the acquisition value significantly from an initial $4.9 billion to the final bid of $10 billion, valuing Metsera at $65.60 per share in cash plus a contingent value right worth up to $20.65 per share [1][2]. Group 1: Acquisition Details - The acquisition process began on October 30 when Novo Nordisk made an unsolicited bid of $6.5 billion, which led to Pfizer increasing its offer to $8.1 billion before Novo raised its bid to $10 billion [5]. - Metsera's stock price peaked at $83.86 after its IPO in January, which was priced at $18 [5]. - The acquisition is expected to close promptly after the stockholder meeting scheduled for November 13, with Metsera expressing confidence in the merger's value for its shareholders [4]. Group 2: Product and Market Implications - Metsera's lead product is a GLP-1-mimicking injection, which is similar to Novo's Wegovy but may offer a monthly dosage compared to Wegovy's weekly administration [3]. - Pfizer aims to enhance its position in the obesity treatment market through this acquisition, especially after facing setbacks with its experimental drugs [6]. - The weight-loss drug market is projected to reach $150 billion by 2035, indicating significant growth potential in this sector [8].